Payment overview · 2025
General Payments
$206.84
11 reported records · 5 companies
Healthcare provider profile · identity verified
Ben E Owens, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JONESBORO, AR · NPI 1679569156
Verified facts
What the public records show
CMS Open Payments records show Ben E Owens, MD received $206.84 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Nurtec Odt, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 730 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.51 | 33.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.75 | 31.8% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.77 | 13.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.87 | 12.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.94 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.84 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $65.75 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.75 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 730 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 100 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
100 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
730 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1417 | 316 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1130 | 225 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1052 | 217 |
| Gabapentin | Gabapentin | 985 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 979 | 235 |
| Potassium Chloride | Potassium Chloride | 923 | 199 |
| Furosemide | Furosemide | 862 | 190 |
| Pantoprazole Sodium | Pantoprazole Sodium | 828 | 176 |
| Omeprazole | Omeprazole | 752 | 160 |
| Eliquis | Apixaban | 730 | 99 |
| Alprazolam | Alprazolam | 704 | 116 |
| Lisinopril | Lisinopril | 696 | 153 |
| Metformin Hcl | Metformin Hcl | 510 | 117 |
| Losartan Potassium | Losartan Potassium | 504 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 468 | 99 |
| Trazodone Hcl | Trazodone Hcl | 421 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 393 | 86 |
| Carvedilol | Carvedilol | 383 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 343 | 84 |
| Pregabalin | Pregabalin | 341 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 329 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 329 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 328 | 65 |
| Donepezil Hcl | Donepezil Hcl | 321 | 70 |
| Meloxicam | Meloxicam | 317 | 74 |
| Jardiance | Empagliflozin | 310 | 52 |
| Ezetimibe | Ezetimibe | 300 | 68 |
| Tramadol Hcl | Tramadol Hcl | 299 | 79 |
| Glipizide | Glipizide | 270 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 260 | 55 |
| Spironolactone | Spironolactone | 260 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 237 | 53 |
| Methylprednisolone | Methylprednisolone | 237 | 186 |
| Fluticasone Propionate | Fluticasone Propionate | 232 | 70 |
| Clonazepam | Clonazepam | 231 | 34 |
| Allopurinol | Allopurinol | 219 | 46 |
| Memantine Hcl | Memantine Hcl | 218 | 49 |
| Lorazepam | Lorazepam | 216 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 207 | 47 |
| Montelukast Sodium | Montelukast Sodium | 205 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 205 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 53 |
| Buspirone Hcl | Buspirone Hcl | 200 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 193 | 41 |
| Celecoxib | Celecoxib | 181 | 37 |
| Doxycycline Hyclate | Doxycycline Hyclate | 180 | 132 |
| Mirtazapine | Mirtazapine | 180 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 50 |
| Atenolol | Atenolol | 166 | 27 |
| Levetiracetam | Levetiracetam | 165 | 27 |
| Simvastatin | Simvastatin | 162 | 43 |
| Alendronate Sodium | Alendronate Sodium | 157 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 155 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 153 | 96 |
| Ropinirole Hcl | Ropinirole Hcl | 150 | 25 |
| Sertraline Hcl | Sertraline Hcl | 147 | 40 |
| Clonidine Hcl | Clonidine Hcl | 145 | 34 |
| Ozempic | Semaglutide | 141 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 140 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 42 |
| Myrbetriq | Mirabegron | 132 | 22 |
| Promethazine Hcl | Promethazine Hcl | 130 | 27 |
| Diazepam | Diazepam | 129 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 124 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 123 | 63 |
| Azithromycin | Azithromycin | 122 | 96 |
| Amiodarone Hcl | Amiodarone Hcl | 116 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 115 | 27 |
| Primidone | Primidone | 115 | 23 |
| Sotalol | Sotalol Hcl | 113 | 22 |
| Famotidine | Famotidine | 110 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 110 | 26 |
| Estradiol | Estradiol | 105 | 16 |
| Nystatin | Nystatin | 102 | 54 |
| Entresto | Sacubitril/Valsartan | 100 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 98 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 22 |
| Carisoprodol | Carisoprodol | 97 | 12 |
| Warfarin Sodium | Warfarin Sodium | 97 | 14 |
| Fenofibrate | Fenofibrate | 96 | 20 |
| Prednisone | Prednisone | 95 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 17 |
| Labetalol Hcl | Labetalol Hcl | 90 | 18 |
| Fentanyl | Fentanyl | 87 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 24 |
| Xarelto | Rivaroxaban | 85 | 11 |
| Finasteride | Finasteride | 84 | 22 |
| Meclizine Hcl | Meclizine Hcl | 83 | 30 |
| Ondansetron Odt | Ondansetron | 82 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 75 | 17 |
| Metformin Hcl Er | Metformin Hcl | 73 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 72 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 16 |
| Linzess | Linaclotide | 70 | 15 |
| Cephalexin | Cephalexin | 69 | 51 |
| Synthroid | Levothyroxine Sodium | 69 | 12 |
| Lamotrigine | Lamotrigine | 68 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 67 | 27 |
| Fluconazole | Fluconazole | 66 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 65 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Baclofen | Baclofen | 63 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 16 |
| Divalproex Sodium | Divalproex Sodium | 61 | 12 |
| Farxiga | Dapagliflozin Propanediol | 61 | suppressed |
| Carbamazepine | Carbamazepine | 60 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | 18 |
| Bupropion Xl | Bupropion Hcl | 59 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 13 |
| Midodrine Hcl | Midodrine Hcl | 58 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 57 | 13 |
| Topiramate | Topiramate | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 15 |
| Sucralfate | Sucralfate | 52 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 11 |
| Brilinta | Ticagrelor | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 12 |
| Calcitriol | Calcitriol | 48 | 11 |
| Methocarbamol | Methocarbamol | 46 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Nitroglycerin | Nitroglycerin | 45 | 32 |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 43 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 39 | 12 |
| Temazepam | Temazepam | 39 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 36 | suppressed |
| Minoxidil | Minoxidil | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 35 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Latanoprost | Latanoprost | 34 | 12 |
| Methadone Hcl | Methadone Hcl | 34 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | 11 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Morphine Sulfate | Morphine Sulfate | 29 | 22 |
| Oxycontin | Oxycodone Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Lacosamide | Lacosamide | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 14 |
| Megestrol Acetate | Megestrol Acetate | 26 | 15 |
| Nyamyc | Nystatin | 26 | 13 |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Austedo | Deutetrabenazine | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Tetrabenazine | Tetrabenazine | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.84 · 11 records | ABBVIE INC. | ELIQUIS, ENTRESTO, INSPIRE, LEQVIO, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error